Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes

Retina

Volumn 31, Issue 2, 2011, Pages 393-400

  Goldenberg, David T ^a   Giblin, Frank J ^b   Cheng, Mei ^b   Chintala, Shravan K ^b   Trese, Michael T ^a,b   Drenser, Kimberly A ^a,b   Ruby, Alan J ^a  

^a Associated Retinal Consultants   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

Avastin; Bevacizumab; microplasmin; posterior vitreous detachment; retinal penetration

Indexed keywords

BEVACIZUMAB; FLUORESCENT DYE; OCRIPLASMIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; AUTOFLUORESCENCE IMAGING; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG PENETRATION; EYE INJURY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MICROSCOPY; NONHUMAN; RETINA; VITREOUS BODY DETACHMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBRINOLYSIN; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; INTRAVITREAL INJECTIONS; PEPTIDE FRAGMENTS; RABBITS; RECOMBINANT PROTEINS; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY; VITREOUS DETACHMENT;

EID: 79551508943     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181e586b2     Document Type: Article

References (37)

1. Friedman DS, O'Colmain DB, Muñoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572.
2. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992;99:933-943.
3. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642.
4. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-118.
5. Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 2008;115:1837-1846.
6. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina 2006;26:383-390.
7. Arevalo JF, Fromow-Guerra J, Sanchez JG, et al. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina 2008;28:1387-1394.
8. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
9. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006;26:994-998.
10. Mittra RA, Pollack JS, eds. Preferences and trends survey. Poster presented at: 26th Annual ASRS meeting; October 11-15, 2008; Maui, Hawaii.
11. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.
12. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-2823.
13. Goldenberg DT, Trese MT. Pharmacologic vitreodynamics: what is it? Why is it important? Expert Rev Ophthalmol 2008; 3:273-277.
14. Nagai N, Demarsin E, Van Hoef B, et al. Recombinant human microplasmin: production and potential therapeutic properties. Thromb Haemost 2003;1:307-313.
15. Sebag J. Molecular biology of pharmacologic vitreolysis. Trans Am Ophthalmol Soc 2005;103:473-494.
16. Sebag J, Ansari RR, Suh KI. Pharmacologic vitreolysis with microplasmin increases vitreous diffusion coefficients. Graefes Arch Clin Exp Ophthalmol 2007;245:576-580.
17. Sakuma T, Tanaka M, Mizota A, Inoue J, Pakola S. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. Invest Ophthalmol Vis Sci 2005;46: 3295-3299.
18. Gandorfer A, Rohleder M, Sethi C, et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci 2004;45:641-647.
19. Quiram PA, Leverenz VR, Baker RM, Dang L, Giblin FJ, Trese MT. Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels. Retina 2007;27:1090-1096.
20. GiblinFJ, QuiramPA,LeverenzVR, BakerRM, DangL, TreseMT. Enzyme-induced posterior vitreous detachment in the rat produces increased lens nuclear pO2 levels. Exp Eye Res 2009; 88:286-292.
21. Wilkinson CP, Rice TA. Michels Retinal Detachment. 2rd ed. St Louis, MO: Mosby; 1997;9-17.
22. Takeuchi A, Kricorian G, Yao XY, Kenny JW, Marmor MF. The rate and source of albumin entry into saline-filled experimental retinal detachments. Invest Ophthalmol Vis Sci 1994;35:3792-3798.
23. Kohno T, Sorgente N, Ishibashi T, et al. Immunofluorescent studies of fibronectin and laminin in the human eye. Invest Ophthalmol Vis Sci 1987;28:506-514.
24. Kamei M, Misono K, Lewis H. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. AmJ Ophthalmol 1999;128:739-746.
25. Rostagno A, Williams M, Frangione B, Gold LI. Biochemical analysis of the interaction of fibronectin with IgG and localization of the respective binding sites. Mol Immunol 1996;33:561-572.
26. Rostagno AA, Frangione B, Gold L. Biochemical studies on the interaction of fibronectin with Ig. J Immunol 1991;146: 2687-2693.
27. Rostagno AA, Frangione B, Gold LI. Biochemical characterization of the fibronectin binding sites for IgG. J Immunol 1989;143:3277-3282.
28. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981;41: 4629-4636.
29. Uemura A, Nakamura M, Kachi S, et al. Effect of plasmin on laminin and fibronectin during plasmin-assisted vitrectomy. Arch Ophthalmol 2005;123:209-213.
30. Stefánsson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol 2009;247:147-163.
31. Peters S, Heiduschka P, Julien S, Bartz-Schmidt KU, Schraermeyer U. Immunohistochemical localization of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye. Br J Ophthalmol 2008; 92:541-544.
32. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27:1260-1266.
33. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.
34. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50: 4807-4813.
35. Ondes F, Yilmaz G, Acar MA, Unlu N, Kocaoglan H, Arsan AK. Role of the vitreous in age-related macular degeneration. Jpn J Ophthalmol 2000;44:91-93.
36. Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol 2007;144:741-746.
37. Quaranta-El MM, Mauget-Faÿsse M. Anomalous vitreoretinal adhesions in patients with exudative age-related macular degeneration: an OCT study. Eur J Ophthalmol 2006;16: 134-137.